Future Science Group
2 files

Supplementary Figures – FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study

posted on 2022-05-24, 10:13 authored by Figshare Future Science GroupFigshare Future Science Group, Alberto Servetto, Antonio Santaniello, Fabiana Napolitano, Francesca Foschini, Roberta Marciano, Priscilla Cascetta, Anna Rita Amato, Maria Rosaria Augurio, Lucia Maresca, Pietro De Placido, Sabino De Placido, Luigi Formisano, Roberto Bianco

 Figure 1: the efficacy of second-line treatment is not affected by responses in the first-line setting. Survival outcomes of the second-line regimens FFN and FOLFOX/CAPOX/FOLFIRI were not affected by the number of cycles of first-line NabGem 

Figure 2:  The mPFS2 and mOS2 of patients treated with second-line NabGem were 14.43 weeks and 21.28 weeks, respectively